Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The deal includes upfront payments, milestone payments and ongoing royalties
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Subscribe To Our Newsletter & Stay Updated
